Patient outcomes in myeloproliferative neoplasm-related thrombosis: Insights from the National Inpatient Sample

Among a sampling of 31,302 patients with Philadelphia chromosome–negative myeloproliferative neoplasms, a recent study found that inpatient mortality was significantly higher among individuals who experienced thrombosis associated with admission compared with those hospitalized for other reasons (5.7% vs. 3.1%, P < 0.001), as well as unadjusted cost of care ($25,539.06 vs $19,002.72 USD, respectively; P < 0.001). Length of stay was also longer, although not significantly, among patients with thrombosis (8.26 vs. 7.95 days, respectively; P = 0.0963).